Jean-Charles Naouri and the French grocer that he led for three decades will stand trial in Paris over allegations he conspired to manipulate Casino’s stock price https://t.co/KX0lrVHvhe ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Zynex, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Company Overview - Zynex, Inc. is facing scrutiny for allegedly inflating its stock price through false and misleading statements regarding its financial performance and operational practices [6] - The company reportedly engaged in a systemic "oversupplying scheme," shipping excessive quantities of supplies and billing insurers for inflated amounts [6] Financial Impact - The misconduct was revealed on March 11, 2025, when Zynex announced a significant revenue shortfall attributed to slower payments from insurers, particularly Tricare, which accounts for 20-25% of its annual revenue [6] - Following the announcement, Zynex's stock price dropped by $3.59 per share, or 51.3%, closing at $3.41 per share, resulting in a substantial loss of shareholder value [6]

Core Viewpoint - Quantum BioPharma Ltd. has made a strategic investment by purchasing 2,000 shares of GameStop Corp. to enhance shareholder value and combat market corruption [1][4]. Group 1: Strategic Investments - The acquisition of GameStop shares is part of Quantum BioPharma's strategy to deploy capital towards undervalued assets with strong fundamentals [4]. - Kevin Malone, Board Advisor, highlighted the value in GameStop, noting that the company holds 90% cash and marketable securities on its balance sheet [5]. Group 2: Advocacy Against Market Manipulation - Quantum BioPharma has appointed advocates like Kevin Malone and Terry Lynch to combat market corruption, particularly against naked short selling and stock manipulation [2]. - The company has filed an amended complaint seeking damages exceeding $700 million against CIBC World Markets and RBC Dominion Securities for alleged stock price manipulation through spoofing techniques [3]. Group 3: Shareholder Value Initiatives - The company is advancing its Multiple Sclerosis Patented New Chemical Entity asset and intends to declare a special dividend tied to potential litigation settlements [4]. - Quantum BioPharma has completed a debt settlement by issuing Class B shares, further demonstrating its commitment to prudent financial management [6]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation in multiple sclerosis [8]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and has a royalty agreement for sales from its product unbuzzd™ [8].

Core Viewpoint - Jim Cramer has raised concerns about the manipulation of Nvidia's stock price, particularly in the pre-market sessions leading up to significant events like the GPU Technology Conference (GTC) [1][2][3] Group 1: Stock Performance - Nvidia's stock has experienced a notable decline, falling 22.27% from its all-time high (ATH) of $153.13 achieved on January 6, 2025, to a current price of $119.03 [5] - Year-to-date, Nvidia shares are down 11.36%, indicating a struggle to maintain positive momentum in 2025 [5] Group 2: Market Dynamics - Cramer highlighted that the stock price of Nvidia was artificially inflated in the pre-market on minimal capital, suggesting that it does not require significant investment to influence the price of a multi-trillion dollar company [2][3] - The volume of trades during extended sessions is significantly lower than during regular trading hours, which means that individual trades can have a disproportionate effect on stock prices [3][4] Group 3: External Factors - The decline in Nvidia's stock can be attributed to various factors, including increased competition from China, the ongoing trade war, a general loss of confidence in the U.S. economy, valuation concerns, and issues related to the launch of new products [6]